Navigation Links
Aromasin Reduced Breast Cancer Risk in Postmenopausal Women
Date:6/5/2011

By Amanda Gardner
HealthDay Reporter

SATURDAY, June 4 (HealthDay News) -- The anti-estrogen drug Aromasin appears to cut the odds of breast cancer by 65 percent in high-risk postmenopausal women, new research has found.

And unlike other anti-estrogen therapies such as tamoxifen and raloxifene, Aromasin (exemestane) did not carry a heightened risk of endocrine cancer or blood clots, although it did have the well-known problems of hot flashes and joint stiffness also attributable to tamoxifen and raloxifene, the study authors said.

Estrogen is a primary fuel behind many breast cancers.

"This may add another potential drug for these women," said Dr. Jennifer Litton, a breast medical oncologist with the University of Texas M.D. Anderson Cancer Center in Houston. "Hot flashes, joint stiffness were more pronounced but it [Aromasin] doesn't have the blood clot and uterine cancer risk."

Aromasin, an aromatase inhibitor now available in generic form, is currently approved for early breast cancer patients but not to prevent tumors.

This new trial, the results of which were presented Saturday at the annual meeting of the American Society of Clinical Oncology in Chicago, is the first to look at drug's use for prevention. The study results were published simultaneously in the New England Journal of Medicine.

Tamoxifen and its sister drug, raloxifene, which combat estrogen by a different mechanism, are approved for breast cancer prevention in high-risk women but both have serious, albeit rare, side effects, including endometrial cancer and blood clots.

Tamoxifen has been shown to reduce the risk of invasive breast cancer by 38 percent, but the risk of side effects seems to have deterred many women. Only 4 percent of women eligible to take tamoxifen actually do so, noted Dr. Paul E. Goss, lead author of the new study and professor of medicine at Harvard Medical School and Massachusetts General Hospital in Boston, who spoke at a Saturday news conference.

The new phase 3 trial of 4,560 women -- all of whom were at higher risk for breast cancer for various reasons including age (average age of the participants was 62.5 years) -- were randomly chosen to take Aromasin or a placebo.

After an average follow-up of three years, investigators found a 65 percent reduction in invasive breast cancer in the Aromasin group compared to the placebo group, a difference Goss characterized as "massive."

The researchers had hoped that osteoporosis and cardiovascular side effects would be lower in the Aromasin portion of the trial but they were not.

Litton stressed, however, that the follow-up in the study was relatively short: only three years and that patients do need to be followed for longer.

The trial was partially funded by Pfizer Inc., which makes Aromasin.

A second study presented Saturday found that expanding the area of radiation in certain women with early breast cancer decreased both local and distant recurrences.

Right now, women whose cancer has spread to more than three lymph nodes are generally treated with surgery and chemotherapy followed by radiation to the whole breast and nearby lymph nodes.

Women with fewer than three positive nodes generally don't get the added radiation.

This randomized study of more than 1,800 women found that expanding the field of radiation in women with fewer positive lymph nodes did, in fact, result in benefits.

After an average follow-up of five years, women with fewer positive lymph nodes who received the additional radiation improved their disease-free survival by more than 30 percent, had a 41 percent lower risk of nearby recurrences and a 36 percent lower rate of distant recurrences.

Improvements in overall survival, however, were not statistically significant, said study lead investigator Dr. Timothy J. Whelan, professor of oncology and division head of radiation oncology at McMaster University and the Juravinski Cancer Centre, in Hamilton, Ontario, Canada.

There were also some side effects in women who received the extra radiation, namely lymphedema (swelling in the arms or legs) and lung inflammation.

Still, Whalen said, "this suggests that all women with node-positive disease be offered regional nodal irradiation as long as they are made aware of the potential toxicities."

More information

The U.S. National Cancer Institute has more on breast cancer.

SOURCES: Jennifer Litton, M.D., breast medical oncologist, University of Texas M.D. Anderson Cancer Center, Houston; June 4, 2011, teleconference with Paul E. Goss, M.D., Ph.D., professor of medicine, Harvard Medical School and Massachusetts General Hospital, Boston and Timothy J. Whelan, BM BCh, professor of oncology and division head of radiation oncology, McMaster University and the Juravinski Cancer Centre, Hamilton, Ontario; June 4, 2011, presentation, American Society of Clinical Oncology annual meeting, Chicago; June 4, 2011, New England Journal of Medicine


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Coffee Drinking and Caffeine Associated With Reduced Risk of Hospitalization for Heart Rhythm Disturbances
2. Risk for patients in the intensive care unit clearly reduced
3. Snoring Reduced With Relaxation Tea… Could It Be?
4. Mount Sinai study finds only a weak link between fruit and vegetable and reduced risk of cancer
5. The association between sleep disturbances and reduced quality of life varies by race
6. Study: Carbon Monoxide Exposure Can be Reduced During Routine Anesthesia in Kids
7. Study: Yogurt-like drink DanActive reduced rate of common infections in daycare children
8. Scientific Study Reveals that 79 Percent of Electronic Cigarette Users Have Stopped or Reduced Their Tobacco Use
9. Mothers high blood sugar in pregnancy is linked to childrens reduced insulin sensitivity
10. "Miracle" Tapping Technique EFT Found to Help Stress, Anxiety, Depression, Trauma and Pain in Reduced Timescales. Workshops Now Offered
11. Obesity is associated with reduced sensitivity to fat
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... ... February 05, 2016 , ... Freed-Hardeman University President Joe ... signed a joint enrollment and degree completion agreement. The agreement, which begins ... degrees at FHU|Dickson. , The agreement allows students to be jointly admitted ...
(Date:2/5/2016)... ... February 05, 2016 , ... In the fourth ... country gathered at the La Valencia Hotel in San Diego, California to discuss ... named the year’s most outstanding franchise, walking away with the coveted David Wright ...
(Date:2/5/2016)... SARASOTA, Fla., (PRWEB) , ... February 05, 2016 , ... ... appetizing recipes just in time for this weekend’s Big Game. Take the stress out ... ingredients that will keep your guests happy at every stage of the game. , ...
(Date:2/5/2016)... ... February 05, 2016 , ... Stuart Bentkover, MD, FACS is ... to provide the most effective tattoo removal today, Dr. Bentkover is the only doctor ... by Cynosure, the PicoSure has been approved by the Food and Drug Administration (FDA) ...
(Date:2/5/2016)... ... February 05, 2016 , ... Health and wellness is a topic that should ... event they are experiencing an illness. Migraines are a severe form of a headache ... migraines would not wish the pain on their worst enemy, the feeling can last ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)... Calif. , Feb. 4, 2016  Edwards Lifesciences ... patient-focused innovations for structural heart disease and critical care ... accelerated share repurchase (ASR) agreement with Morgan Stanley & ... stock.  This repurchase is part of the Company,s previously ... the Company,s common stock.  --> ...
(Date:2/4/2016)... Feb. 4, 2016 Worldwide Radiology Oncology ... growth as next generation systems provide a way ... for cancer surgery. New systems pinpoint the delivery ... has been such a problem previously, limiting the ... robots take cancer surgery far beyond what has ...
(Date:2/4/2016)... Calif. , Feb. 4, 2016  SciClone ... today announced it has entered into a settlement ... Commission (SEC) fully resolving the SEC,s investigation into ... (FCPA).  Under the terms of the settlement agreement, ... $12.8 million, including disgorgement, pre-judgment interest and a ...
Breaking Medicine Technology: